Search

Your search keyword '"Hasseine, Lilia"' showing total 43 results
Start Over Author "Hasseine, Lilia"
43 results on '"Hasseine, Lilia"'

1. Laboratory practices for the diagnosis and management of mucormycosis in France, 2024

Author

Millon, Laurence, Botterel, Françoise, Bonhomme, Julie, Valot, Stéphane, Poirier, Philippe, Durieux, Marie-Fleur, Bigot, Jeanne, Desoubeaux, Guillaume, Chesnais, Adélaïde, Morio, Florent, Pihet, Marc, Brunet, Kévin, Bellanger, Anne-Pauline, Imbert, Sébastien, Nevez, Gilles, Gal, Solène Le, Bourgeois, Nathalie, Debourgogne, Anne, Cornu, Marjorie, Persat, Florence, Hasseine, Lilia, Bougnoux, Marie-Elisabeth, Brun, Sophie, Cornet, Muriel, Favennec, Loïc, Gargala, Gilles, Bonnal, Christine, Gangneux, Jean-Pierre, Alanio, Alexandre, Iriart, Xavier, Mahinc, Caroline, Chouaki, Taieb, Paugam, André, Letscher-Bru, Valérie, and Dannaoui, Eric

Published
2024
Full Text
View/download PDF

2. Epidemiology and prognostic factors of mucormycosis in France (2012–2022): a cross-sectional study nested in a prospective surveillance programme

Author

Gouzien, Laura, Che, Didier, Cassaing, Sophie, Lortholary, Olivier, Letscher-Bru, Valérie, Paccoud, Olivier, Obadia, Thomas, Morio, Florent, Moniot, Maxime, Cateau, Estelle, Bougnoux, Marie Elisabeth, Chouaki, Taieb, Hasseine, Lilia, Desoubeaux, Guillaume, Gautier, Cecile, Mahinc-Martin, Caroline, Huguenin, Antoine, Bonhomme, Julie, Sitbon, Karine, Durand, Julien, Alanio, Alexandre, Millon, Laurence, Garcia-Hermoso, Dea, and Lanternier, Fanny

Published
2024
Full Text
View/download PDF

3. Evaluation of a New Histoplasma spp. Quantitative RT-PCR Assay

Author

Woimant, Marine Gosset, blanchard, Geneviève, Silhadi, Souad, Vignier, Nicolas, Pitsch, Aurelia, Jidar, Kaoutar, Traversier, Nicolas, Poisson, Didier, Lecointre, Claire, Foulet, Françoise, Botterel, Françoise, Ammar, Nawel Ait, Amsellem, Gabriel, Frederic, Poirier, Philipe, Cornu, Marjorie, Loridant, Severine, Morio, Florent, Boutoille, David, Jeddi, Fakhri, Hasseine, Lilia, Ouissa, Rachida, Toubas, Dominique, Bailly, Eric, Désoubeaux, Guillaume, Ronez, Emily, Foulon, Guillaume, Lefrançois, Sebastien, Bonnal, Christine, Paugam, André, Dougados, Maxime, Desroches, Marine, Barazzutti, Hélène, Paleiron, Nicolas, rabodonirina, Meja, Catherinot, Emilie, Cardot-Martin, Emilie, Hiesse, Chrisian, Salvator, Hélène, Aguilar, Claire, Gigandon, Anne, de Montpreville, Thomas, Bougnoux, Marie-Elisabeth, Sitterlé, Emilie, Fekkar, Arnaud, Imbert, Sébastien, Bleibtreu, Alexandre, Senghor, Yaye, Denis, Blandine, Molina, Jean-Michel, Liegeon, Geoffroy, Munnier, Anne-Lise, Malphettes, Marion, Denis, Julie, Berlioz-Arthaud, Alain, Lange, Franciska, Chiaruzzi, Myriam, Epelboin, Loic, Alanio, Alexandre, Gits-Muselli, Maud, Lanternier, Fanny, Sturny-Leclère, Aude, Benazra, Marion, Hamane, Samia, Rodrigues, Anderson Messias, Garcia-Hermoso, Dea, Lortholary, Olivier, Dromer, Françoise, and Bretagne, Stéphane

Published
2021
Full Text
View/download PDF

4. Features of cryptococcosis among 652 HIV-seronegative individuals in France: a cross-sectional observational study (2005-2020)

Author

Paccoud, Olivier, primary, Desnos-Ollivier, Marie, additional, Persat, Florence, additional, Demar, Magalie, additional, Boukris-Sitbon, Karine, additional, Bellanger, Anne-Pauline, additional, Bonhomme, Julie, additional, Bonnal, Christine, additional, Botterel, Françoise, additional, Bougnoux, Marie-Elisabeth, additional, Brun, Sophie, additional, Cassaing, Sophie, additional, Cateau, Estelle, additional, Chouaki, Taieb, additional, Cornet, Muriel, additional, Dannaoui, Eric, additional, Desbois-Nogard, Nicole, additional, Durieux, Marie-Fleur, additional, Favennec, Loïc, additional, Fekkar, Arnaud, additional, Gabriel, Frederic, additional, Gangneux, Jean-Pierre, additional, Guitard, Juliette, additional, Hasseine, Lilia, additional, Huguenin, Antoine, additional, Le Gal, Solène, additional, Letscher-Bru, Valérie, additional, Mahinc, Caroline, additional, Morio, Florent, additional, Nicolas, Muriel, additional, Poirier, Philippe, additional, Ranque, Stéphane, additional, Roosen, Gabrielle, additional, Rouges, Célia, additional, Roux, Anne-Laure, additional, Sasso, Milène, additional, Alanio, Alexandre, additional, Lortholary, Olivier, additional, Lanternier, Fanny, additional, Brieu, N., additional, Durand, C., additional, Bertei, D., additional, Bouchara, J.P., additional, Pihet, M., additional, Bland, S., additional, Bru (Annecy), J.P., additional, Pulik, M., additional, Le Turdu, F., additional, Lefrand, C, H., additional, Ferrand, M., additional, Larrouy, M., additional, Millon, L., additional, Delhaes, L., additional, Imbert, S., additional, Accoceberry, I., additional, Bachelier, M.N., additional, Nevez, G., additional, Quinio, D., additional, Le Coustumier, A., additional, Carmagnol, F., additional, Rivière, B., additional, Boex, P., additional, Podac, B., additional, Moniot, M., additional, Nourrisson, C., additional, Augereau, O., additional, Emond, J.P., additional, Belkacem-Belkaki, G., additional, Bacri, J.L., additional, Berthelot, G., additional, Dalle, F., additional, Vallee, E., additional, Bizet, J., additional, Noussair, L., additional, Herrmann, J.L., additional, Maubon, D., additional, Brocard, C., additional, Guiffault, P., additional, Layet, A., additional, Morel, A., additional, Angoulvant, A., additional, Penn, P., additional, Gigandon, A., additional, Sendid, B., additional, Cornu, M., additional, Darde, M.L., additional, Jaccard, A., additional, Bouteille, B., additional, Azjenberg, D., additional, Prades, N., additional, Bienvenu, A.L., additional, Benoit-Cattin, T., additional, Fiacre, A., additional, Levy, S., additional, Pitsch, A., additional, Kiefer, M.H., additional, Debourgogne, A., additional, Moquet, O., additional, Colot, J., additional, Courtellemont, L., additional, Poisson, D., additional, Laurens, V., additional, Kauffmann-Lacroix, C., additional, Martres, P., additional, Gargala, G., additional, Godineau, N., additional, Picot, S., additional, Chassagne, C., additional, Djibo, N., additional, Devallière, R., additional, Sabou, M., additional, Camin-Ravenne, A.M., additional, Bissuel, F., additional, Janvier, F., additional, Aubert, X., additional, Chadapaud, S., additional, Delbeck, X., additional, Lafeuillade, A., additional, Raoult, X., additional, Baclet, V., additional, Coignard, C., additional, Mouton, Y., additional, Ravaux, I., additional, Eloy, C., additional, Fur, A., additional, Rezzouk, L., additional, Mazards, E., additional, Eloy, O., additional, Chachaty, E., additional, Mihaila, L., additional, Dellion, S., additional, Patey, O., additional, Thouvenot, A., additional, Limousin, L., additional, Paugam, A., additional, Desplaces, N., additional, Raguin, G., additional, Sitterlé, E., additional, Blaize, M., additional, Gits-Muselli, M., additional, Hennequin, C., additional, Poirot, J.L., additional, Bretagne, S., additional, Lacroix, Claire, additional, and Hamane, Samia, additional

Published
2024
Full Text
View/download PDF

5. Gradient concentration strip–specific epidemiological cut-off values of antifungal drugs in various yeast species and five prevalent Aspergillus species complexes

Author

Mercier, Victor, Letscher-Bru, Valérie, Bougnoux, Marie-Elisabeth, Delhaes, Laurence, Botterel, Francoise, Maubon, Danièle, Dalle, Frédéric, Alanio, Alexandre, Houzé, Sandrine, Dannaoui, Eric, Cassagne, Carole, Cassaing, Sophie, Durieux, Marie-Fleur, Fekkar, Arnaud, Bouchara, Jean-Philippe, Gangneux, Jean-Pierre, Bonhomme, Julie, Dupont, Damien, Costa, Damien, Sendid, Boualem, Chouaki, Taieb, Bourgeois, Nathalie, Huguenin, Antoine, Brun, Sophie, Mahinc, Caroline, Hasseine, Lilia, Le Gal, Solène, Bellanger, Anne-Pauline, Bailly, Eric, Morio, Florent, Nourrisson, Céline, Desbois-Nogard, Nicole, Perraud-Cateau, Estelle, Debourgogne, Anne, Yéra, Hélène, Lachaud, Laurence, and Sasso, Milène

Published
2023
Full Text
View/download PDF

6. Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

Author

Galmiche, Simon, primary, Thoreau, Benjamin, additional, Bretagne, Stéphane, additional, Alanio, Alexandre, additional, Paugam, André, additional, Letscher-Bru, Valérie, additional, Cassaing, Sophie, additional, Gangneux, Jean-Pierre, additional, Guegan, Hélène, additional, Favennec, Loïc, additional, Minoza, Alida, additional, Morio, Florent, additional, Bonhomme, Julie, additional, Desoubeaux, Guillaume, additional, Eloy, Odile, additional, Hasseine, Lilia, additional, Sasso, Milène, additional, Millon, Laurence, additional, Bellanger, Anne-Pauline, additional, Poirier, Philippe, additional, Moniot, Maxime, additional, Chouaki, Taieb, additional, Huguenin, Antoine, additional, Dalle, Frédéric, additional, Bouteille, Bernard, additional, Nicolas, Muriel, additional, Desbois-Nogard, Nicole, additional, Bougnoux, Marie-Elisabeth, additional, Danion, François, additional, Poindron, Vincent, additional, Néel, Antoine, additional, Boukris-Sitbon, Karine, additional, Lanternier, Fanny, additional, and Terrier, Benjamin, additional

Published
2023
Full Text
View/download PDF

8. High negative predictive value diagnostic strategies for the reevaluation of early antifungal treatment: A multicenter prospective trial in patients at risk for invasive fungal infections

Author

Sirvent, Anne, Mondain, Véronique, Hyvernat, Hervé, Rosenthal, Eric, Cointault, Olivier, Lavayssière, Laurence, Georges, Bernard, Berry, Antoine, de Guibert, Sophie, Nimubona, Stanislas, Revest, Matthieu, Tattevin, Pierre, Hasseine, Lilia, Cassaing, Sophie, Robert-Gangneux, Florence, Fillaux, Judith, Marty, Pierre, and Gangneux, Jean-Pierre

Published
2015
Full Text
View/download PDF

9. Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018)

Author

Bretagne, Stéphane, Sitbon, Karine, Desnos-Ollivier, Marie, Garcia-Hermoso, Dea, Letscher-Bru, Valérie, Cassaing, Sophie, Millon, Laurence, Morio, Florent, Gangneux, Jean-Pierre, Hasseine, Lilia, Favennec, Loïc, Cateau, Estelle, Bailly, Eric, Moniot, Maxime, Bonhomme, Julie, Desbois-Nogard, Nicole, Chouaki, Taieb, Paugam, André, Bouteille, Bernard, Pihet, Marc, Dalle, Frédéric, Eloy, Odile, Sasso, Milène, Demar, Magalie, Mariani-Kurkdjian, Patricia, Robert, Vincent, Lortholary, Olivier, Dromer, Françoise, French Mycoses Study Group, The, Damiani, Céline, Dupont, Hervé, Maizel, Julien, Totet, Anne, Bouchara, Jean-Philippe, Bellanger, Anne Pauline, Berceanu, Ana, Navellou, Jean Christophe, Scherer, Emeline, Abboud, Philippe, Aznar, Christine, Blanchet, Denis, Djossou, Félix, Cayot, Sophie, Garrouste, Cyril, Lesens, Olivier, Moluçon, Cécile, Nourrisson, Céline, Poirier, Philippe, Bailly, Éloïse, Basmaciyan, Louise, Belaid, Bouhemad, Blot, Mathieu, Caillot, Denis, Charles, Pierre-Emmanuel, Quenot, Jean Pierre, Amazan, Emmanuelle, Baubion, Emilie, Cabie, André, Chabartier, Cyrille, Deligny, Christophe, Emal, Violaine, Flechelle, Olivier, Hatchuel, Yves, Le Govic, Yohann, Merle, Harold, Miossec, Charline, Turmel, Jean-Marie, Valentino, Ruddy, Durieux, Marie-Fleur, Turlure, Pascal, Mercier, Victor, Gari-Toussaint, Martine, Risso, Karine, Simon, Loïc, Bretonnière, Cedric, Boutoille, David, Gastinne, Thomas, Lakhal, Karim, Launay, Elise, Lepoivre, Thierry, Peterlin, Pierre, Rialland, Fanny, Le Pape, Patrice, Canoui, Etienne, Dahane, Naima, Kerneis, Solène, Angebault, Cécile, Bougnoux, Marie-Elisabethh, Guennouni, Nadia, Lanternier, Fanny, Neven, Bennedicte, Oualha, Mehdi, Scemla, Anne, Sitterlé, Emilie, Suarez, Felipe, Toubiana, Julie, Bonacorci, Stéphane, Alanio, Alexandre, Bergeron, Anne, Denis, Blandine, Gits-Muselli, Maud, Hamane, Samia, Touratier, Sophie, Chaumeil, Christine, Merabet, Lilia, Claudéon, Joelle, Curlier, Elodie, Galantine, Valérie, Gallois, Jean Claude, Markowicz, Samuel, Nicolas, Muriel, Musson, Pascal, Schepers, Kinda, Minoza, Alida, Kauffmann-Lacroix, Catherine, Guégan, Hélène, Costa, Damien, Dehais, Marion, Gargala, Gilles, Bajolet, Odile, Banisadr, Firouze, Cousson, Joel, Himberlin, Chantal, Huguenin, Antoine, Toubas, Dominique, Flori, Pierre, Mahinc, Caroline, Raberin, Hélène, Denis, Julie, Herbrecht, Raoul, Mertes, Paul-Michel, Meziani, Fehrat, Sabou, Marcela, Schneider, Francis, Bertozzi, Anne-Isabelle, Chauvin, Pamela, Charpentier, Elena, Cointault, Olivier, Cottrel, Claire, Delavigne, Karen, Faguer, Stanislas, Fillaux, Judith, Guemas, Emilie, Iriart, Xavier, Lelièvre, Lucie, Ruiz, Jean, Bastides, Frédéric, Chesnay, Adélaïde, Desoubeaux, Guillaume, Therby, Audrey, Chachaty, Elisabeth, Gachot, Bertrand, Westerdijk Fungal Biodiversity Institute, Westerdijk Fungal Biodiversity Institute - Software and Databasing, Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Dynamique des interactions hôte pathogène (DIHP), Université de Strasbourg (UNISTRA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Nantes Université (Nantes Univ), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Rouen, Normandie Université (NU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Ecologie et biologie des interactions (EBI), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Clermont-Ferrand, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU de la Martinique [Fort de France], CHU Amiens-Picardie, Hôpital Cochin [AP-HP], CHU Limoges, SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), Laboratoire de Parasitologie-Mycologie (CHU d'Angers), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Infections Respiratoires Fongiques (IRF), Université d'Angers (UA)-Université de Brest (UBO), Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université de Bourgogne (UB)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Centre Hospitalier de Versailles André Mignot (CHV), Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Hôpital Robert Debré Paris, Hôpital Robert Debré, Westerdijk Fungal Biodiversity Institute [Utrecht] (WI), Royal Netherlands Academy of Arts and Sciences (KNAW), Service des Maladies infectieuses et tropicales [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Simplification des soins chez les patients complexes - UR UPJV 7518 (SSPC), Université de Picardie Jules Verne (UPJV), Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Laboratoire de Parasitologie-Mycologie [CHU Angers], Hôpital Bretonneau, Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by recurrent financial support from Santé Publique France and Institut Pasteur. The funders had no role in study design, data collection, analysis, interpretation of data, or the decision to submit the work for publication., We thank Didier Che (Direction des Maladies Infectieuses, Santé Publique France) for his continuous support and interest in invasive fungal infections and Etienne Sevin (EpiConcept, Paris, France) for his contribution in the development of the RESSIF website using the VOOZANOO platform. We are thankful for the technical help of Catherine Blanc, Anne Boullié, Cécile Gautier, Virginie Geolier, and Damien Hoinard (Institut Pasteur) for the characterization of the isolates received at the NRCMA., The French Mycoses Study Group includes collaborators who contributed to these data by their involvement in the management of patients, expertise in diagnostic tools, and/or characterization of fungal isolates. They are listed in alphabetical order of a city in France and for each center, in alphabetical order of the last names: in Amiens, Céline Damiani, Hervé Dupont, Julien Maizel, and Anne Totet, in Angers, Jean-Philippe Bouchara, in Besançon, Anne Pauline Bellanger, Ana Berceanu, Jean Christophe Navellou, and Emeline Scherer, in Cayenne, Philippe Abboud, Christine Aznar, Denis Blanchet, and Félix Djossou, in Clermont-Ferrand, Sophie Cayot, Cyril Garrouste, Olivier Lesens, Cécile Moluçon, Céline Nourrisson, and Philippe Poirier, in Dijon, Éloïse Bailly, Louise Basmaciyan, Bouhemad Belaid, Mathieu Blot, Denis Caillot, Pierre-Emmanuel Charles, and Jean Pierre Quenot, in Fort de France, Emmanuelle Amazan, Emilie Baubion, André Cabie, Cyrille Chabartier, Christophe Deligny, Violaine Emal, Olivier Flechelle, Yves Hatchuel, Yohann Le Govic, Harold Merle, Charline Miossec, Jean-Marie Turmel, and Ruddy Valentino, in Limoges, Marie-Fleur Durieux and Pascal Turlure, in Nîmes, Victor Mercier, in Nice, Martine Gari-Toussaint, Karine Risso, and Loïc Simon, in Nantes, Cedric Bretonnière, David Boutoille, Thomas Gastinne, Karim Lakhal, Elise Launay, Thierry Lepoivre, Pierre Peterlin, Fanny Rialland, and Patrice Le Pape, in Paris, in Hôpital Cochin, Etienne Canoui, Naima Dahane, and Solène Kerneis, in Hôpital Necker-Enfants Malades, Cécile Angebault, Marie-Elisabethh Bougnoux, Nadia Guennouni, Fanny Lanternier, Bennedicte Neven, Mehdi Oualha, Anne Scemla, Emilie Sitterlé, Felipe Suarez, and Julie Toubiana, in Hôpital Robert-Debré, Stéphane Bonacorci, in Hôpital Saint-Louis, Alexandre Alanio, Anne Bergeron, Blandine Denis, Maud Gits-Muselli, Samia Hamane, and Sophie Touratier, in hôpital des XV-XX, Christine Chaumeil and Lilia Merabet, in Pointe-à-Pitre, Joelle Claudéon, Elodie Curlier, Valérie Galantine, Jean Claude Gallois, Samuel Markowicz, Muriel Nicolas, Pascal Musson, and Kinda Schepers, in Poitiers, Alida Minoza and Catherine Kauffmann-Lacroix, in Rennes, Hélène Guégan, in Rouen, Damien Costa, Marion Dehais, and Gilles Gargala, in Reims, Odile Bajolet, Firouze Banisadr, Joel Cousson, Chantal Himberlin, Antoine Huguenin, and Dominique Toubas, in Saint Etienne, Pierre Flori, Caroline Mahinc, and Hélène Raberin, in Strabourg, Julie Denis, Raoul Herbrecht, Paul-Michel Mertes, Fehrat Meziani, Marcela Sabou, and Francis Schneider, in Toulouse, Anne-Isabelle Bertozzi, Pamela Chauvin, Elena Charpentier, Olivier Cointault, Claire Cottrel, Karen Delavigne, Stanislas Faguer, Judith Fillaux, Emilie Guemas, Xavier Iriart, Lucie Lelièvre, and Jean Ruiz, in Tours, Frédéric Bastides, Adélaïde Chesnay, and Guillaume Desoubeaux, in Versailles, Audrey Therby, and in Villejuif, Elisabeth Chachaty and Bertrand Gachot., and CLEMENT, Nathalie

Subjects
Antifungal Agents, pneumocytosis, invasive fungal infections, Pneumonia, Pneumocystis, [SDV]Life Sciences [q-bio], candidemia, Microbiology, [SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, mucormycosis, [SDV] Life Sciences [q-bio], [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Virology, Humans, aspergillosis, epidemiology, Watchful Waiting, Fungemia, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Aged
Abstract

International audience; The French National Reference Center for Invasive Mycoses and Antifungals leads an active and sustained nationwide surveillance program on probable and proven invasive fungal diseases (IFDs) to determine their epidemiology in France. Between 2012 and 2018, a total of 10,886 IFDs were recorded. The incidence increased slightly over time (2.16 to 2.36/10,000 hospitalization days, P = 0.0562) in relation with an increase of fungemia incidence (1.03 to 1.19/10,000, P = 0.0023), while that of other IFDs remained stable. The proportion of ≥65-year-old patients increased from 38.4% to 45.3% (P < 0.0001). Yeast fungemia (n = 5,444) was due mainly to Candida albicans (55.6%) with stable proportions of species over time. Echinocandins became the main drug prescribed (46.7% to 61.8%), but global mortality rate remained unchanged (36.3% at 1 month). Pneumocystis jirovecii pneumonia (n = 2,106) was diagnosed mostly in HIV-negative patients (80.7%) with a significantly higher mortality than in HIV-positive patients (21.9% versus 5.4% at 1 month, P < 0.0001). Invasive aspergillosis (n = 1,661) and mucormycosis (n = 314) were diagnosed mostly in hematology (>60% of the cases) with a global mortality rate of 42.5% and 59.3%, respectively, at 3 months and significant changes in diagnosis procedure over time. More concurrent infections were also diagnosed over time (from 5.4% to 9.4% for mold IFDs, P = 0.0115). In conclusion, we observed an aging of patients with IFD with a significant increase in incidence only for yeast fungemia, a trend toward more concurrent infections, which raises diagnostic and therapeutic issues. Overall, global survival associated with IFDs has not improved despite updated guidelines and new diagnostic tools.IMPORTANCE The epidemiology of invasive fungal diseases (IFDs) is hard to delineate given the difficulties in ascertaining the diagnosis that is often based on the confrontation of clinical and microbiological criteria. The present report underlines the interest of active surveillance involving mycologists and clinicians to describe the global incidence and that of the main IFDs. Globally, although the incidence of Pneumocystis pneumonia, invasive aspergillosis, and mucormycosis remained stable over the study period (2012 to 2018), that of yeast fungemia increased slightly. We also show here that IFDs seem to affect older people more frequently. The most worrisome observation is the lack of improvement in the global survival rate associated with IFDs despite the increasing use of more sensitive diagnostic tools, the availability of new antifungal drugs very active in clinical trials, and a still low/marginal rate of acquired in vitro resistance in France. Therefore, other tracks of improvement should be investigated actively.

Published
2022
Full Text
View/download PDF

11. Species Identification and In Vitro Antifungal Susceptibility of Paecilomyces/Purpureocillium Species Isolated from Clinical Respiratory Samples: A Multicenter Study

Author

Monpierre, Lorra, primary, Aït-Ammar, Nawel, additional, Valsecchi, Isabel, additional, Normand, Anne-Cécile, additional, Guitard, Juliette, additional, Riat, Arnaud, additional, Huguenin, Antoine, additional, Bonnal, Christine, additional, Sendid, Boualem, additional, Hasseine, Lilia, additional, Raberin, Hélène, additional, Dehais, Marion, additional, Ranque, Stéphane, additional, Hennequin, Christophe, additional, Piarroux, Renaud, additional, Dannaoui, Eric, additional, and Botterel, Françoise, additional

Published
2022
Full Text
View/download PDF

12. Cryptococcal Meningitis in Kidney Transplant Recipients: A Two-Decade Cohort Study in France

Author

Tardieu, Laurène, primary, Divard, Gillian, additional, Lortholary, Olivier, additional, Scemla, Anne, additional, Rondeau, Éric, additional, Accoceberry, Isabelle, additional, Agbonon, Rémi, additional, Alanio, Alexandre, additional, Angoulvant, Adela, additional, Albano, Laetitia, additional, Attias, Philippe, additional, Bellanger, Anne Pauline, additional, Bertrand, Dominique, additional, Bonhomme, Julie, additional, Botterel, Françoise, additional, Bouvier, Nicolas, additional, Buchler, Matthias, additional, Chouaki, Taieb, additional, Crépin, Thomas, additional, Durieux, Marie-Fleur, additional, Desoubeaux, Guillaume, additional, Doppelt, Gary, additional, Favennec, Loïc, additional, Fekkar, Arnaud, additional, Fourdinier, Ophélie, additional, Frimat, Marie, additional, Gangneux, Jean-Pierre, additional, Garandeau, Claire, additional, Hasseine, Lilia, additional, Hennequin, Christophe, additional, Iriart, Xavier, additional, Kamar, Nassim, additional, Kaminski, Hannah, additional, Kormann, Raphael, additional, Lachaud, Laurence, additional, Legendre, Christophe, additional, Le Quintrec Donnette, Moglie, additional, Leroy, Jordan, additional, Levi, Charlène, additional, Machouart, Marie, additional, Marx, David, additional, Menotti, Jean, additional, Moal, Valérie, additional, Morio, Florent, additional, Mrozek, Natacha, additional, Nicolas, Muriel, additional, Poirier, Philippe, additional, Peraldi, Marie-Noelle, additional, Poussot, Benjamin, additional, Ranque, Stéphane, additional, Rerolle, Jean-Philippe, additional, Sendid, Boualem, additional, Snanoudj, Renaud, additional, Tourret, Jérôme, additional, Vasse, Marc, additional, Vigneau, Cécile, additional, Villard, Odile, additional, Mesnard, Laurent, additional, Lanternier, Fanny, additional, and Rafat, Cédric, additional

Published
2022
Full Text
View/download PDF

13. COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave

Author

Bretagne, Stéphane, Sitbon, Karine, Botterel, Françoise, Dellière, Sarah, Letscher-Bru, Valérie, Chouaki, Taieb, Bellanger, Anne-Pauline, Bonnal, Christine, Fekkar, Arnault, Persat, Florence, Costa, Damien, Bourgeois, Nathalie, Dalle, Frédéric, Lussac-Sorton, Florian, Paugam, André, Cassaing, Sophie, Hasseine, Lilia, Huguenin, Antoine, Guennouni, Nadia, Mazars, Edith, Le Gal, Solène, Sasso, Milène, Brun, Sophie, Cadot, Lucile, Cassagne, Carole, Cateau, Estelle, Gangneux, Jean-Pierre, Moniot, Maxime, Roux, Anne-Laure, Tournus, Céline, Desbois-Nogard, Nicole, Le Coustumier, Alain, Moquet, Olivier, Alanio, Alexandre, Dromer, Françoise, Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Génomique évolutive, modélisation et santé (GEMS), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire - Molecular Mycology, CHU Henri Mondor [Créteil], Laboratoire de Parasitologie et de Mycologie Médicale [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Laboratoire de parasitologie et de mycologie médicales [CHU Amiens], CHU Amiens-Picardie, Service de parasitologie et mycologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de parasitologie et mycologie médicale [Hôpital de la Croix Rousse, Lyon], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Rouen, Normandie Université (NU), Laboratoire de Parasitologie-Mycologie (CHU de Montpellier), Pôle Biologie-Pathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de parasitologie mycologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire de Parasitologie-Mycologie, Nice, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Centre Hospitalier Universitaire de Reims (CHU Reims), Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Université de Reims Champagne-Ardenne (URCA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Necker - Enfants Malades [AP-HP], Centre hospitalier [Valenciennes, Nord], Laboratoire de Parasitologie et Mycologiede [CHRU Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Parasitologie [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Clermont-Ferrand, Hôpital Raymond Poincaré [AP-HP], Hôpital Ambroise Paré [AP-HP], Centre Hospitalier de Saint-Denis [Ile-de-France], Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Centre Hospitalier de Beauvais, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), The NRCMA is supported by Santé Publique France and Institut Pasteur, Institut Pasteur [Paris], Génomique évolutive, modélisation et santé (CNRS-UMR2000), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor, Service de parasitologie - mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et de Maladies Infectieuses (CIMI), CHU Toulouse [Toulouse], Université Nice Sophia Antipolis (... - 2019) (UNS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Service de Parasitologie - Mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Gestionnaire, Hal Sorbonne Université, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Hôpital Henri Mondor, Laboratoire de parasitologie et mycologie médicale [CHU Strasbourg], CHU Strasbourg, Service de Parasitologie Mycologie[Bichat], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]

Subjects
Male, Antifungal Agents, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Mannans, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: COVID-19, aspergillosis, MESH: Treatment Outcome, MESH: Aged, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, MESH: Middle Aged, fungemia, Coinfection, Pneumonia, Pneumocystis, Middle Aged, QR1-502, Intensive Care Units, Treatment Outcome, Aspergillus, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, MESH: Pulmonary Aspergillosis, France, Research Article, MESH: Galactose, Microbiology, pneumocystosis, MESH: Mannans, MESH: Critical Care, MESH: Fungemia, Humans, MESH: SARS-CoV-2, Aged, Retrospective Studies, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, MESH: Humans, SARS-CoV-2, Galactose, COVID-19, MESH: Retrospective Studies, MESH: Antifungal Agents, MESH: Male, MESH: Coinfection, MESH: France, critical care, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH: Intensive Care Units, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Pulmonary Aspergillosis, MESH: Female, MESH: Pneumonia, Pneumocystis
Abstract

International audience; The aim of this study was to evaluate diagnostic means, host factors, delay of occurrence, and outcome of patients with COVID-19 pneumonia and fungal coinfections in the intensive care unit (ICU). From 1 February to 31 May 2020, we anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia (CA-fungemia), and pneumocystosis (CA-PCP) from 36 centers, including results on fungal biomarkers in respiratory specimens and serum. We collected data from 154 episodes of CAPA, 81 of CA-fungemia, 17 of CA-PCP, and 5 of other mold infections from 244 patients (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years). CA-PCP occurred first after ICU admission (median, 1 day; interquartile range [IQR], 0 to 3 days), followed by CAPA (9 days; IQR, 5 to 13 days), and then CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10-4). For CAPA, the presence of several mycological criteria was associated with death (P < 10-4). Serum galactomannan was rarely positive (

Published
2021
Full Text
View/download PDF

14. Antifungal Susceptibility of 182 Fusarium Species Isolates from 20 European Centers: Comparison between EUCAST and Gradient Concentration Strip Methods

Author

Blaize, Marion, primary, Normand, Anne-Cecile, additional, Imbert, Sebastien, additional, Al-Hatmi, Abdullah M. S., additional, Chryssanthou, Erja, additional, Cassaing, Sophie, additional, Schuttler, Christine, additional, Hasseine, Lilia, additional, Mahinc, Caroline, additional, Costa, Damien, additional, Bonnal, Christine, additional, Ranque, Stéphane, additional, Sautour, Marc, additional, Rubio, Elisa, additional, Delhaes, Laurence, additional, Riat, Arnaud, additional, Sendid, Boualem, additional, Kristensen, Lise, additional, Brandenberger, Marcel, additional, Stubbe, Dirk, additional, Brun, Sophie, additional, Piarroux, Renaud, additional, and Fekkar, Arnaud, additional

Published
2021
Full Text
View/download PDF

15. Paludisme d’aéroport

Author

Queyriaux, Benjamin, Pradines, Bruno, Hasseine, Lilia, Coste, Sébastien, Rodriguez, Patrick, Coffinet, Thierry, Haus-Cheymol, Rachel, and Rogier, Christophe

Published
2009
Full Text
View/download PDF

16. Invasive aspergillosis due to Aspergillus cryptic species: A prospective multicentre study

Author

Imbert, Sebastien, primary, Cassaing, Sophie, additional, Bonnal, Christine, additional, Normand, Anne‐Cecile, additional, Gabriel, Frederic, additional, Costa, Damien, additional, Blaize, Marion, additional, Lachaud, Laurence, additional, Hasseine, Lilia, additional, Kristensen, Lise, additional, Guitard, Juliette, additional, Schuttler, Christine, additional, Raberin, Helene, additional, Brun, Sophie, additional, Hendrickx, Marijke, additional, Piarroux, Renaud, additional, and Fekkar, Arnaud, additional

Published
2021
Full Text
View/download PDF

17. Clinical Origin and Species Distribution of Fusarium spp. Isolates Identified by Molecular Sequencing and Mass Spectrometry: A European Multicenter Hospital Prospective Study

Author

Normand, Anne-Cécile, primary, Imbert, Sébastien, additional, Brun, Sophie, additional, Al-Hatmi, Abdullah M. S., additional, Chryssanthou, Erja, additional, Cassaing, Sophie, additional, Schuttler, Christine, additional, Hasseine, Lilia, additional, Mahinc, Caroline, additional, Costa, Damien, additional, Bonnal, Christine, additional, Ranque, Stéphane, additional, Sautour, Marc, additional, Rubio, Elisa, additional, Delhaes, Laurence, additional, Riat, Arnaud, additional, Sendid, Boualem, additional, Kristensen, Lise, additional, Brandenberger, Marcel, additional, Guitard, Juliette, additional, Packeu, Ann, additional, Piarroux, Renaud, additional, and Fekkar, Arnaud, additional

Published
2021
Full Text
View/download PDF

18. Species Identification and In Vitro Antifungal Susceptibility of Paecilomyces / Purpureocillium Species Isolated from Clinical Respiratory Samples: A Multicenter Study.

Author

Monpierre, Lorra, Aït-Ammar, Nawel, Valsecchi, Isabel, Normand, Anne-Cécile, Guitard, Juliette, Riat, Arnaud, Huguenin, Antoine, Bonnal, Christine, Sendid, Boualem, Hasseine, Lilia, Raberin, Hélène, Dehais, Marion, Ranque, Stéphane, Hennequin, Christophe, Piarroux, Renaud, Dannaoui, Eric, and Botterel, Françoise

Subjects
PAECILOMYCES, ANTIFUNGAL agents, SPECIES, CANDIDEMIA, AMPHOTERICIN B, MASS spectrometry, ECHINOCANDINS
Abstract

Paecilomyces spp. are emerging fungal pathogens, where Paecilomyces lilacinus and Paecilomyces variotii are the most reported species. Taxonomic and phylogenetic revisions in this genus have shown that P. variotii represents a species complex, whereas P. lilacinus is related to another genus called Purpureocillium. The aims of this study were to identify clinical isolates of Paecilomyces spp. at the species level, and to determine their antifungal susceptibility profiles. 70 clinical Paecilomyces spp. isolates were identified by MALDI-TOF Mass Spectrometry (MS) and by multilocus rDNA genes sequencing including ITS and the D1/D2 genes. Among the 70 Paecilomyces spp. isolates, 28 were identified as P. lilacinum, 26 as P. variotii stricto sensu, and 16 as P. maximus. For antifungal susceptibility testing, Minimal Inhibitory Concentrations (MICs) or Minimal Effective Concentrations (MECs) were determined for 8 antifungals. All P. lilacinum isolates had high MICs and MECs of amphotericin B and echinocandins, respectively, unlike P. variotii and P. maximus. For azole drugs, MICs were molecule- and species- dependent. The differences in in vitro susceptibility to antifungals underline the importance of accurate species identification. The MALDI–TOF MS can be a good alternative in routine laboratory to ensure fast identification of Paecilomyces spp. and P. lilacinum. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. PCR and culture for diagnosis of Acanthamoeba keratitis

Author

Yera, Helene, primary, Ok, Vichita, additional, Lee Koy Kuet, Fiona, additional, Dahane, Naima, additional, Ariey, Frédéric, additional, Hasseine, Lilia, additional, Delaunay, Pascal, additional, Martiano, David, additional, Marty, Pierre, additional, and Bourges, Jean Louis, additional

Published
2020
Full Text
View/download PDF

22. PCR and culture for diagnosis of Acanthamoeba keratitis.

Author

Yera, Helene, Ok, Vichita, Kuet, Fiona Lee Koy, Dahane, Naima, Ariey, Frédéric, Hasseine, Lilia, Delaunay, Pascal, Martiano, David, Marty, Pierre, and Bourges, Jean Louis

Abstract

Background/Aims Acanthamoeba keratitis (AK) is a rare but sightthreatening infection. Molecular diagnosis of corneal scraping has improved the diagnosis of AK. Different molecular targets and conditions have been used in diagnosis thus far. In this study, we prospectively compared the performance of five PCR assays on corneal samples for the diagnosis of AK. Methods 1217 corneal scraping samples were obtained from patients, for whom an AK was suspected. Sample processing involved both molecular diagnostics and culture. Acanthamoeba PCR assays detected different regions of the Acanthamoeba nuclear small-subunit rRNA gene: three final point PCR assays using Nelson, ACARNA and JDP1-JDP2 pairs of primers, and two real-time PCR assays using Acant primer-probe. Human DNA and internal control were co-amplified in the real-time PCR assay to ensure scraping quality and the absence of inhibitors. In the absence of a gold standard, the performance of each test was evaluated using latent class analysis. Genotypes of Acanthamoeba isolates were also characterised. Results Estimated prevalence of AK was 1.32%. The sensitivity of Acanthamoeba diagnostic PCRs (73.3% to 86.7%) did not differ significantly from that of culture (66.7%), or according to the target sequence or the technology. Sensitivity could be increased to 93.8% or 100% by combining two or three assays, respectively. PCR specificity (99.3% to 100%) differed between the assays. T4 was the predominant Acanthamoeba genotype (84.6%). Conclusions Culture and a single PCR assay could lead to misdiagnosing AK. A combination of different PCR assays and improved sample quality could increase diagnosis sensitivity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. Multi-centric evaluation of the online MSI platform for the identification of cryptic and rare species of Aspergillus by MALDI-TOF

Author

Imbert, Sébastien, primary, Normand, Anne Cécile, additional, Gabriel, Frédéric, additional, Cassaing, Sophie, additional, Bonnal, Christine, additional, Costa, Damien, additional, Lachaud, Laurence, additional, Hasseine, Lilia, additional, Kristensen, Lise, additional, Schuttler, Christine, additional, Raberin, Hélène, additional, Brun, Sophie, additional, Hendrickx, Marijke, additional, Stubbe, Dirk, additional, Piarroux, Renaud, additional, and Fekkar, Arnaud, additional

Published
2019
Full Text
View/download PDF

25. Evaluation of a New Histoplasmaspp. Quantitative RT-PCR Assay

Author

Alanio, Alexandre, Gits-Muselli, Maud, Lanternier, Fanny, Sturny-Leclère, Aude, Benazra, Marion, Hamane, Samia, Rodrigues, Anderson Messias, Garcia-Hermoso, Dea, Lortholary, Olivier, Dromer, Françoise, Bretagne, Stéphane, Woimant, Marine Gosset, blanchard, Geneviève, Silhadi, Souad, Vignier, Nicolas, Pitsch, Aurelia, Jidar, Kaoutar, Traversier, Nicolas, Poisson, Didier, Lecointre, Claire, Foulet, Françoise, Botterel, Françoise, Ammar, Nawel Ait, Amsellem, Gabriel, Frederic, Poirier, Philipe, Cornu, Marjorie, Loridant, Severine, Morio, Florent, Boutoille, David, Jeddi, Fakhri, Hasseine, Lilia, Ouissa, Rachida, Toubas, Dominique, Bailly, Eric, Désoubeaux, Guillaume, Ronez, Emily, Foulon, Guillaume, Lefrançois, Sebastien, Bonnal, Christine, Paugam, André, Dougados, Maxime, Desroches, Marine, Barazzutti, Hélène, Paleiron, Nicolas, rabodonirina, Meja, Catherinot, Emilie, Cardot-Martin, Emilie, Hiesse, Chrisian, Salvator, Hélène, Aguilar, Claire, Gigandon, Anne, de Montpreville, Thomas, Bougnoux, Marie-Elisabeth, Sitterlé, Emilie, Fekkar, Arnaud, Imbert, Sébastien, Bleibtreu, Alexandre, Senghor, Yaye, Denis, Blandine, Molina, Jean-Michel, Liegeon, Geoffroy, Munnier, Anne-Lise, Malphettes, Marion, Denis, Julie, Berlioz-Arthaud, Alain, Lange, Franciska, Chiaruzzi, Myriam, and Epelboin, Loic

Abstract

Laboratory diagnosis of histoplasmosis is based on various methods, including microscopy, culture, antigen, and DNA detection of Histoplasma capsulatumvar. capsulatumor Histoplasma capsulatumvar. duboisii. To improve sensitivity of existing real-time quantitative PCR (qPCR) assays, we developed a new RT-qPCR assay that allows amplification of whole nucleic acids of Histoplasmaspp. validated on suspected cases. The limit of detection was 20 copies, and the specificity against 114 fungal isolates/species was restricted to Histoplasmaspp. Whole nucleic acids of 1319 prospectively collected consecutive samples from 907 patients suspected of having histoplasmosis were tested routinely between May 2015 and May 2019 in parallel with standard diagnostic procedures performed in parallel. Forty-four had proven histoplasmosis attributable to H. capsulatumvar. capsulatum(n= 40) or H. capsulatumvar. duboisii(n= 4) infections. The results of RT-qPCR were positive in 43 of 44 patients (97.7% sensitivity) in at least one specimen. Nine of 863 cases (99% specificity) were RT-qPCR positive and therefore classified as possible cases. RT-qPCR was positive in 13 of 30 (43.3%) blood samples tested in proven cases. A positive RT-qPCR result in blood was significantly associated with H. capsulatumvar. capsulatumprogressively disseminated histoplasmosis with a positive RT-qPCR result in 92.3% of the immunocompromised patients with disseminated disease. This new HistoplasmaRT-qPCR assay enabling amplification of H. capsulatumvar. capsulatumand H. capsulatumvar. duboisiiis highly sensitive and allows the diagnosis of histoplasmosis advantageously from blood and bronchoalveolar lavage fluid.

Published
2021
Full Text
View/download PDF

27. Identification en ligne des agents fongiques par spectrométrie de masse et détection d’espèces émergentes

Author

Normand, Anne-Cécile, primary, Cassagne, Carole, additional, Hasseine, Lilia, additional, Gari-Toussaint, Martine, additional, Gabriel, Frédéric, additional, Accoceberry, Isabelle, additional, Costa, Damien, additional, Bourgeois, Nathalie, additional, Cassaing, Sophie, additional, Nabet, Cécile, additional, Bonnal, Christine, additional, Raberin, Hélène, additional, Stein, Markus, additional, Surmont, Ignace, additional, Pierard, Denis, additional, Djenad, Farid, additional, Donnadieu, Jean-Luc, additional, Piarroux, Martine, additional, Ranque, Stéphane, additional, Becker, Pierre, additional, Hendrickx, Marijke, additional, and Piarroux, Renaud, additional

Published
2017
Full Text
View/download PDF

29. A misleading false-negative result of Pneumocystis real-time PCR assay due to a rare punctual mutation: A French multicenter study

Author

Le Gal, Solène, primary, Robert-Gangneux, Florence, additional, Pépino, Yann, additional, Belaz, Sorya, additional, Damiani, Céline, additional, Guéguen, Paul, additional, Pitous, Mélanie, additional, Virmaux, Michèle, additional, Lissillour, Eloise, additional, Pougnet, Laurence, additional, Guillaud-Saumur, Thibaud, additional, Toubas, Dominique, additional, Valot, Stéphane, additional, Hennequin, Christophe, additional, Morio, Florent, additional, Hasseine, Lilia, additional, Bouchara, Jean-Philippe, additional, Totet, Anne, additional, and Nevez, Gilles, additional

Published
2016
Full Text
View/download PDF

30. Toxoplasmosis and horse meat, France

Author

Pomares, Christelle, Ajzenberg, Daniel, Bornard, Loic, Bernardin, Gilles, Hasseine, Lilia, Darde, Marie-Laure, and Marty, Pierre

Subjects
Horse meat -- Health aspects -- Research, Toxoplasmosis -- Risk factors -- Diagnosis -- Research, Polymerase chain reaction -- Usage, Health
Abstract

To the Editor: Toxoplasma gondii parasites are obligate intracellular apicomplexans that can infect virtually all warm-blooded animals; felids are definitive hosts. The most common sources of human infection are ingestion [...]

Published
2011
Full Text
View/download PDF

31. High negative predictive value diagnostic strategies for the reevaluation of early antifungal treatment: A multicenter prospective trial in patients at risk for invasive fungal infections

Author

Hasseine, Lilia, primary, Cassaing, Sophie, additional, Robert-Gangneux, Florence, additional, Fillaux, Judith, additional, Marty, Pierre, additional, Gangneux, Jean-Pierre, additional, Sirvent, Anne, additional, Mondain, Véronique, additional, Hyvernat, Hervé, additional, Rosenthal, Eric, additional, Cointault, Olivier, additional, Lavayssière, Laurence, additional, Georges, Bernard, additional, Berry, Antoine, additional, de Guibert, Sophie, additional, Nimubona, Stanislas, additional, Revest, Matthieu, additional, and Tattevin, Pierre, additional

Published
2015
Full Text
View/download PDF

33. Multicenter prospective monitoring for empirical treatment of invasive fungal infection using high negative predictive value diagnostic strategies

Author

Hasseine, Lilia, Marty, P., Cassaing, Sophie, Robert-Gangneux, Florence, Gaudron, L., Knecht, R., Bonesso, L., Linas, Marie-Denise, Berry, A., Gangneux, Jean-Pierre, Brébion, Alice, Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), and Université de Rennes (UR)

Subjects
[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology
Published
2010

34. Sinusite maxillaire récidivante et Schizophyllum commune

Author

Gari-Toussaint, Martine, Hasseine, Lilia, Castillo, L., Pihet, Marc, Bouchara, Jean-Philippe, Laboratory of Mycology, Archet II Hospital, Centre Hospitalier Universitaire de Nice (CHU Nice), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2010

35. Evaluation d'une méthode d'extraction d'ADN fongique à partir de sang total en vue d'une contribution au diagnostic des mycoses systémiques

Author

Hasseine, Lilia, Knecht, R., Grimbert, S., Cassaing, Sophie, Robert-Gangneux, Florence, Berry, A., Gangneux, Jean-Pierre, Marty, P., Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de Parasitologie-Mycologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Laboratoire de Parasitologie-Mycologie, Nice, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Université de Rennes (UR), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Université Nice Sophia Antipolis (1965 - 2019) (UNS)

Subjects
[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2009

36. A misleading false-negative result of Pneumocystis real-time PCR assay due to a rare punctual mutation: A French multicenter study.

Author

Le Gal, Solene, Robert-Gangneux, Florence, Pépino, Yann, Belaz, Sorya, Damiani, Celine, Guéguen, Paul, Pitous, Melanie, Virmaux, Michele, Lissillour, Eloise, Pougnet, Laurence, Guillaud-Saumur, Thibaud, Toubas, Dominique, Valot, Stephane, Hennequin, Christophe, Morio, Florent, Hasseine, Lilia, Bouchara, Jean-Philippe, Totet, Anne, and Nevez, Gilles

Abstract

This article describes a previously unreported mutation at position 210 (C210T) of the mi-tochondrial large subunit ribosomal RNA (mtLSUrRNA) gene of Pneumocystis jirovecii, which led to a false-negative result of a real-time polymerase chain reaction (PCR) assay. Since the aforementioned real-time PCR assay is widely used in France, a French multicenter study was conducted to estimate the mutation frequency and its potential impact on the routine diagnosis of Pneumocystis pneumonia (PCP). Through analysis of data obtained from eight centers, the mutation frequency was estimated at 0.28%. This low frequency should not call into question the routine use of this PCR assay. Nonetheless, the occurrence of the false-negative PCR result provides arguments for maintaining microscopic techniques combined to PCR assays to achieve PCP diagnosis. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

37. 195 Impact of a multidisciplinary approach of invasive fungal infections from diagnosis to treatment

Author

Berrouane Yasmina, Sirvent Anne, Poirée Maryline, Gari-Toussaint Martine, Mousnier Aline, Dantin-Delafoulhouze Thomas, Lieutier Florence, Mondain Véronique, Hasseine Lilia, and Lucas-Daver Stéphanie

Subjects
Gynecology, Antifungal, medicine.medical_specialty, Pediatrics, medicine.diagnostic_test, Haematology department, medicine.drug_class, Aspergillus galactomannan antigen assay, business.industry, Health Policy, Authorization, High resolution, Transplantation, Infectious disease specialist, medicine, Blood culture, business
Abstract

Invasive fungal infections (IFI) are severe diseases affecting immuno-compromised patients. In France, since 2007, the cost of expensive recommended antifungal treatments (AFT) is not included in the normal per-case payment and each suspected IFI must be systematically documented during interdisciplinary team meetings (ITM) including an infectious disease specialist, a haematologist, a mycologist and a pharmacist. Objective To evaluate the impact of our ITM. Methods In 2008, 179 advices were provided in real time to prescribing doctors concerning 109 patients receiving AFT. This was done during 31 ITM. From January to September 2009, 192 advices were provided during 27 ITM, Each patient9s condition was documented according to clinical presentation including emergency high resolution CT of the chest and abdomen, microbiological data as Aspergillus galactomannan antigen assay twice a week, pan-fungal PCR, and mycological analysis of various samples (bronchoalveolar fluid, blood culture…). Results In 2008, eight cases of probable and two of possible invasive aspergillosis (IA) were diagnosed (all in a haematology department, with one paediatric case). Four patients died: in one case IA may have been a causative factor. Incidence rate for IA was 4.7% among patients with acute leukaemia and stem-cell transplantation, which seems low compared to the literature. Advices were followed in 90% of cases. In 2008 and 2009 (until September), 95% of treatments involving added costs, were in line with provisions for marketing authorisation. Number of empirical AFT First half the year 2003 19/41(46%) First half the year 2008 7/23(30%) First half the year 2009 9/39(23%) To conclude, currently, 100% of patients benefit from a radiological and biological monitoring, in order to optimise the diagnosis and AFT. Thus, the empirical9s antifungal (AF) number has been reduced from 46 to 23%. Indeed, we observed a 17% drop in added AF costs and 12% for other systemic AF (2007 vs 2008). A good compliance with the suggested advices shows that prescribing doctors are in favour of the scheme. The consumption of AF expressed in Daily Defined Dose will allow further assessment of practice trends. Les MFI sont des pathologies infectieuses severes des patients immunodeprimes. Les traitements antifongiques (AF) systemiques recommandes font partie depuis 2005 des medicaments tarifies en sus de l9activite. Depuis 2005, pour chaque suspicion de MFI une documentation systematique est demandee en cellule antifongiques (RCP hebdomadaire pluridisciplinaire: infectiologue, hematologue, mycologue, pharmacien) et les traitements AF en cours sont discutes. En 2008, 179 avis ont ete communiques en temps reel aux prescripteurs concernant 109 patients traites par AF. Ces avis ont ete donnes au cours de 31 RCP au vu des donnees diagnostiques, microbiologiques et d9imagerie accessibles dans le dossier patient informatise. Lors du 1er semestre 2009, 192 avis donnes au cours de 27 RCP. Les patients ont tous beneficie d9une documentation adaptee a leur etat et a la presentation clinique, avec notamment TDM haute resolution thoraco-abdominale en urgence, antigenemies aspergillaires trois fois par semaine, PCR panfongique, Aspergillus et Candida dans les liquides biologiques. En 2008, 8 diagnostics d9aspergillose invasive (AI) probable ont ete poses, 2 d9AI possible (tous en hematologie, 1 en hematologie pediatrique). 4 patients sont decedes, et pour un l9AI peut avoir constitue un facteur favorisant du deces. L9incidence des AI est de 4,7% parmi les patients presentant une leucemie aigue et greffes de CSH; ce qui semble faible par rapport a la litterature. 90% des avis diagnostiques et therapeutiques ont ete suivis. En 2008 et 1er semestre 2009, 95% des traitements tarifies en sus sont conformes aux AMM. Nb de traitements empiriques par antifongiques: Premier semestre 2003 19/41 (46%) Premier semestre 2008 7/23 (30%) Premier semestre 2009 9/39 (23%) En optimisant la demarche diagnostique et therapeutique, avec aujourd9hui 100% des patients beneficiant de la recherche des criteres microbiologiques et tomodensitometriques, notre action a permis de reduire le nombre de poursuites de traitements empiriques de 46 a 23%, avec pour consequence une reduction de 17% des AF facturables en sus et 12% des autres AF systemiques en 2008 par rapport a 2007. La bonne observance des avis souligne l9adhesion des prescripteurs a notre demarche. Les consommations en AF en doses definies journalieres permettront de preciser mieux encore l9evolution des pratiques.

Published
2010
Full Text
View/download PDF

38. A Cutaneous Ulcer Resulting from Mycobacterium ulcerans—Leishmania braziliensis Coinfection in South America

Author

Mougin, Benjamin, primary, Abgueguen, Pierre, additional, Marty, Pierre, additional, Pomares, Christelle, additional, Chabasse, Dominique, additional, Hasseine, Lilia, additional, Cottin, Jane, additional, Avenel-Audran, Martine, additional, Ravel, Christophe, additional, Martin, Ludovic, additional, and Delaunay, Pascal, additional

Published
2011
Full Text
View/download PDF

40. Epidemiology and Prognostic Factors Associated With Mold-Positive Blood Cultures: 10-Year Data From a French Prospective Surveillance Program (2012-2022).

Author

Tala-Ighil T, Garcia-Hermoso D, Dalle F, Cassaing S, Guitard J, Boukris-Sitbon K, Obadia T, Lortholary O, Letscher-Bru V, Ledoux MP, Chouaki T, Bellanger AP, Rouges C, Bougnoux ME, Moniot M, Pihet M, Dubée V, Gabriel F, Morio F, Hasseine L, Bonnal C, Gits-Muselli M, Perraud-Cateau E, Mahinc C, Nicolas M, Chachaty E, Cordier C, Lachaud L, Courtellemont L, Henry B, Angebault C, Gargala G, Chesnay A, Pacreau ML, Kamus L, Desbois-Nogard N, Demar M, Epelboin L, Alanio A, Dannaoui E, and Lanternier F

Abstract

Background: While invasive fusariosis and lomentosporiosis are known to be associated with fungemia, overall data on mold-related fungemia are limited, hampering early management. This study aimed to describe the epidemiology of mold-positive blood cultures., Methods: Epidemiological and clinical data on mold-positive blood cultures from 2012 to 2022 were obtained from the RESSIF database. Pseudofungemia was excluded using modified Duthie and Denning criteria. Univariable and multivariable Firth logistical regression was used to study factors associated with 90-day mortality., Results: Fusarium spp accounted for 67.5% of the 80 events, involving predominantly Fusarium fujikuroi spp complex (FFSC), Neocosmospora spp, and Fusarium oxysporum spp complex (FOSC). Lomentospora prolificans was the second most frequent (10%), followed by Trichoderma spp, Aspergillus spp, and Mucorales (5% each).Most patients had a history of hematological malignancy (HM) (70%). Forty-three percent had undergone allogeneic hematopoietic stem cell transplantation. Cutaneous and pulmonary lesions were common (43% each). Median time to blood culture positivity was 72 hours.HM and neutropenia were commonly reported in patients with FFSC, Neocosmospora spp, and L. prolificans fungemia. Pulmonary lesions were frequent in cases of L. prolificans fungemia. Patients with gastrointestinal conditions were frequently diagnosed with FOSC molds. HM (75%), particularly acute myeloblastic leukemia, was frequent in patients with Aspergillus spp fungemia. All patients with Trichoderma spp fungemia were exposed to corticosteroids.Day 90 mortality was 53%. Independent predictive factors of day 90 mortality included L. prolificans (odds ratio [OR], 33.3), Aspergillus spp fungemia (OR, 14.2), and corticosteroid exposure (OR, 7.85)., Conclusions: Underlying conditions and clinical presentation vary between genera and could be considered to guide early management., Competing Interests: Potential conflicts of interest . F. D. has received funding from Pfizer for attending scientific events. S. C. has received funding from Gilead and Pfizer for attending scientific events. M.-P. L. has received funding from Gilead, AbbVie, Jazz, Grifols, and Servier for attending scientific events; has received payment from Gilead, Pfizer, Takeda, Servier, and Janssen for lectures; and has participated in advisory boards for AbbVie and Jazz. A. P. B. and C. B. have received funding from Gilead for attending scientific events. V. D. has served as expert witness for Pfizer SAS and Patientys. M. G. M. has received funding from the European Society of Clinical Microbiology and Infectious Diseases for scientific events and payment from Gilead for expert lectures. C. C. has served as unpaid speaker with Gilead. C. A. has received funding for attending scientific events by Gilead and from Pfizer for lectures. A. A. has received payment from Pfizer for educational lectures. E. D. has received funding from Gilead and Mundipharma for attending scientic events, and payment for Mundipharma and bioMérieux for expert lectures. F. L. has served on the speakers bureau and an advisory board for F2G. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2025
Full Text
View/download PDF

41. Cryptococcus neoformans Infections Differ Among Human Immunodeficiency Virus (HIV)-Seropositive and HIV-Seronegative Individuals: Results From a Nationwide Surveillance Program in France.

Author

Paccoud O, Desnos-Ollivier M, Cassaing S, Boukris-Sitbon K, Alanio A, Bellanger AP, Bonnal C, Bonhomme J, Botterel F, Bougnoux ME, Brun S, Chouaki T, Cornet M, Dannaoui E, Demar M, Desbois-Nogard N, Durieux MF, Favennec L, Fekkar A, Gabriel F, Gangneux JP, Guitard J, Hasseine L, Huguenin A, Le Gal S, Letscher-Bru V, Mahinc C, Morio F, Nicolas M, Rouges C, Cateau E, Persat F, Poirier P, Ranque S, Roosen G, Roux AL, Sasso M, Lortholary O, and Lanternier F

Abstract

Among 1107 cryptococcosis cases from the French surveillance network (2005-2020), the proportion of HIV-seronegative individuals has recently surpassed that of HIV-seropositive individuals. We observed marked differences in patient characteristics, disease presentations, cryptococcal antigen results, infecting species, and mortality according to HIV serostatus., Competing Interests: Potential conflicts of interest. Over the past 5 years, E. D. has received research grants from MSD, Gilead, and bioMérieux; travel grants from Gilead, MSD, and Pfizer; and speaker's fees from Gilead and Pfizer. All other authors report no potential conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Published
2023
Full Text
View/download PDF

42. Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018).

Author

Bretagne S, Sitbon K, Desnos-Ollivier M, Garcia-Hermoso D, Letscher-Bru V, Cassaing S, Millon L, Morio F, Gangneux JP, Hasseine L, Favennec L, Cateau E, Bailly E, Moniot M, Bonhomme J, Desbois-Nogard N, Chouaki T, Paugam A, Bouteille B, Pihet M, Dalle F, Eloy O, Sasso M, Demar M, Mariani-Kurkdjian P, Robert V, Lortholary O, and Dromer F

Subjects
Aged, Antifungal Agents therapeutic use, Humans, Watchful Waiting, Aspergillosis drug therapy, Aspergillosis epidemiology, Fungemia drug therapy, Invasive Fungal Infections epidemiology, Mucormycosis drug therapy, Pneumonia, Pneumocystis
Abstract

The French National Reference Center for Invasive Mycoses and Antifungals leads an active and sustained nationwide surveillance program on probable and proven invasive fungal diseases (IFDs) to determine their epidemiology in France. Between 2012 and 2018, a total of 10,886 IFDs were recorded. The incidence increased slightly over time (2.16 to 2.36/10,000 hospitalization days, P  = 0.0562) in relation with an increase of fungemia incidence (1.03 to 1.19/10,000, P  = 0.0023), while that of other IFDs remained stable. The proportion of ≥65-year-old patients increased from 38.4% to 45.3% ( P  < 0.0001). Yeast fungemia ( n  = 5,444) was due mainly to Candida albicans (55.6%) with stable proportions of species over time. Echinocandins became the main drug prescribed (46.7% to 61.8%), but global mortality rate remained unchanged (36.3% at 1 month). Pneumocystis jirovecii pneumonia ( n  = 2,106) was diagnosed mostly in HIV-negative patients (80.7%) with a significantly higher mortality than in HIV-positive patients (21.9% versus 5.4% at 1 month, P  < 0.0001). Invasive aspergillosis ( n  = 1,661) and mucormycosis ( n  = 314) were diagnosed mostly in hematology (>60% of the cases) with a global mortality rate of 42.5% and 59.3%, respectively, at 3 months and significant changes in diagnosis procedure over time. More concurrent infections were also diagnosed over time (from 5.4% to 9.4% for mold IFDs, P  = 0.0115). In conclusion, we observed an aging of patients with IFD with a significant increase in incidence only for yeast fungemia, a trend toward more concurrent infections, which raises diagnostic and therapeutic issues. Overall, global survival associated with IFDs has not improved despite updated guidelines and new diagnostic tools. IMPORTANCE The epidemiology of invasive fungal diseases (IFDs) is hard to delineate given the difficulties in ascertaining the diagnosis that is often based on the confrontation of clinical and microbiological criteria. The present report underlines the interest of active surveillance involving mycologists and clinicians to describe the global incidence and that of the main IFDs. Globally, although the incidence of Pneumocystis pneumonia, invasive aspergillosis, and mucormycosis remained stable over the study period (2012 to 2018), that of yeast fungemia increased slightly. We also show here that IFDs seem to affect older people more frequently. The most worrisome observation is the lack of improvement in the global survival rate associated with IFDs despite the increasing use of more sensitive diagnostic tools, the availability of new antifungal drugs very active in clinical trials, and a still low/marginal rate of acquired in vitro resistance in France. Therefore, other tracks of improvement should be investigated actively.

Published
2022
Full Text
View/download PDF

43. [Airport malaria].

Author

Queyriaux B, Pradines B, Hasseine L, Coste S, Rodriguez P, Coffinet T, Haus-Cheymol R, and Rogier C

Subjects
Animals, Anopheles parasitology, Female, Humans, Malaria microbiology, Malaria parasitology, Male, Plasmodium falciparum isolation & purification, Aviation, Malaria prevention & control
Abstract

Airport malaria is a particular form of autochthonous malaria: it happens when the Plasmodium infected Anopheles genus mosquito travels from an endemic area to a malaria free airport. Since 1969, 30 cases of airport malaria have been reported in France, 2 during summer 2008. The severity of airport malaria is explained by the frequency of Plasmodium falciparum infecting non immune individuals and an often important diagnosis delay. It is a compulsory notification disease in France. The International Health Regulations (IHR) require states to check that airplanes coming from malaria or arboviral endemic area are systematically disinsected. Vector control measures have to be implemented within a distance of at least 400 meters around the perimeter of airports in malaria or arboviral endemic areas. In France, this measure applies to all airports of French overseas territories, except for the island of Saint-Pierre and Miquelon.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results